✦ LIBER ✦

43 Present and future of HIPEC (hyperthermic intraperitoneal chemotherapy) in colorectal carcinomatosis

✍ Scribed by D. Elias

Book ID: 119599812
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 43 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)70049-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neoadjuvant Chemotherapy with Bevacizuma

Neoadjuvant Chemotherapy with Bevacizumab May Improve Outcome after Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Colorectal Carcinomatosis

✍ Ceelen, Wim; Van Nieuwenhove, Yves; Putte, Dirk Vande; Pattyn, Piet 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 252 KB

Is there a role for intraperitoneal admi

Is there a role for intraperitoneal administration of heparin in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal cancer origin? Current data and future orientations

✍ Seretis, Fotios; Seretis, Charalampos 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Cytoreductive surgery and hyperthermic i

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal carcinomatosis: The impact of patients' selection policy on outcome and morbidity

✍ Vaira, M.; Robella, M.; Massucco, P.; Cinquegrana, A.; De Simone, M. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Toxicity of hyperthermic intraperitoneal

Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: Early experience and phase 1 results

✍ A. Hayes-Jordan; H. Green; J. Ludwig; P. Anderson 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Safety and potential benefit of hyperthe

Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer

✍ Franco Roviello; Enrico Pinto; Giovanni Corso; Corrado Pedrazzani; Stefano Carus 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 1 views

## Abstract ## Objectives To analyze the outcomes of cytoreductive surgery and HIPEC in patients with peritoneal carcinomatosis from ovarian cancer. ## Methods Fifty‐three patients with peritoneal carcinomatosis from primary (45 cases) and recurrent (8 cases) ovarian cancer were previously treat

Bevacizumab Doubles the Early Postoperat

Bevacizumab Doubles the Early Postoperative Complication Rate after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis of Colorectal Origin

✍ Eveno, Clarisse; Passot, Guillaume; GoÃ©rÃ©, Diane; Soyer, Philippe; Gayat, Etie 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 220 KB